Browse the evidence

SGLT2 inhibitors reduce blood pressure and body weight in patients with Type 2 Diabetes.

SGLT2 inhibitors can help you lose a small amount of weight (about 1.7 kg or 2.4%) and lower your blood pressure. This is achieved through osmotic diuresis and reduced body fat mass. These effects contribute to overall cardiovascular and renal health.

GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) induce significant weight loss and provide renoprotective effects (reduced albuminuria and slower eGFR decline) in adults with chronic kidney disease (CKD), with efficacy potentially maintained or enhanced in lower eGFR subgroups.

If you have CKD and obesity, newer GLP-1 medications (like semaglutide or tirzepatide) are highly effective for weight loss and may actually protect your kidneys by reducing protein in urine and slowing kidney function decline. Unlike diet and exercise alone, which often fail long-term, these drugs target the hormonal drivers of obesity. Start with a low dose and increase slowly to avoid stomach issues, and stay hydrated to protect your kidneys.

GLP-1 receptor agonists (e.g., liraglutide, semaglutide) resolve MASH histology primarily through substantial weight loss and improved insulin resistance, rather than direct hepatocyte effects.

GLP-1 agonists like semaglutide and liraglutide are effective treatments for MASH, but their primary benefit comes from the weight loss and metabolic improvements they induce, not a direct 'liver cure.' Expect significant weight loss (often 10-15%+), but also manage expectations regarding side effects like nausea, which are common initially. These drugs resolve MASH in a majority of patients but may not reverse advanced fibrosis as effectively. Consult a specialist to determine if the benefits outweigh the burden of injection and side effects for your specific liver stage.

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) produce significant real-world weight loss, but effectiveness is substantially lower than in clinical trials due to high discontinuation rates (20-50%) and suboptimal dosing in routine care.

GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss, but their real-world success depends entirely on sticking with them. Many people stop early due to side effects or cost, leading to less weight loss than seen in trials. To get the best results, you must manage side effects (which often fade) and ensure you can afford the medication long-term. If you adhere to the full dose and stay on the drug, your weight loss can match what is seen in clinical trials.

Obesity increases the risk of kidney stones (nephrolithiasis) through mechanisms including lower urine pH, increased urinary oxalate, uric acid, and sodium excretion, as well as insulin resistance.

Obesity increases your risk of kidney stones by changing your urine chemistry. To protect your kidneys, stay hydrated, limit excessive protein and sodium intake, and manage your weight through balanced nutrition.

High intake of refined carbohydrates, particularly white rice, is strongly associated with an increased risk of metabolic syndrome and type 2 diabetes in Asian populations, whereas complex carbohydrates (brown rice, legumes) are protective.

Not all carbs are created equal. White rice, white bread, and sugary drinks spike your blood sugar and insulin, driving up your risk for diabetes and metabolic syndrome. Switch to complex carbohydrates like brown rice, whole wheat, legumes, and vegetables. These 'good carbs' provide fiber and nutrients that protect against insulin resistance.

Obesity increases the risk and severity of periodontitis through systemic inflammation and adipokine release, creating a bidirectional relationship where higher BMI correlates with poorer periodontal outcomes.

Higher body weight is biologically linked to more severe gum disease due to inflammation. If you are overweight, you are at higher risk for gum bone loss. Managing weight and treating gum disease are interconnected parts of your overall health.

Industrial trans fatty acids (iTFA) increase cardiovascular disease risk by promoting atherosclerosis and inflammation, whereas ruminant trans fatty acids (rTFA) may have neutral or anti-atherogenic effects.

Avoid foods with 'partially hydrogenated oils' as they contain industrial trans fats which increase heart disease risk. However, you do not need to eliminate natural trans fats found in meat and dairy, as they may not have the same negative effects and could potentially be beneficial.

Polyunsaturated fatty acids (PUFAs), particularly n-3 PUFAs like EPA and DHA, protect against ischemia/reperfusion injury and reduce cardiovascular disease risk by modulating inflammation and ion channels.

Increase your intake of n-3 polyunsaturated fatty acids (PUFAs) found in fish (EPA, DHA) and plant sources like flaxseed (ALA). These fats help reduce inflammation and protect the heart during stress events like ischemia. Be mindful of n-6 PUFA intake, as excessive amounts may promote inflammation.

Baseline body mass index (BMI), glycated haemoglobin (HbA1c), and triglyceride levels can accurately predict future glycaemic control trajectories (stable, improved, or deteriorated) in patients with newly diagnosed type 2 diabetes.

If you have been newly diagnosed with type 2 diabetes, your doctor can use three simple numbers from your initial blood work—your BMI, your HbA1c, and your triglycerides—to predict how your blood sugar will likely behave over the next few years. This helps them decide whether you need frequent check-ups or if standard care is sufficient, allowing for more personalized management of your condition.

Low carbohydrate diets facilitate remission of Type 2 diabetes for some individuals, primarily through reducing hepatic and pancreatic fat storage and restoring beta-cell function.

For some people with Type 2 Diabetes, adopting a low carbohydrate diet can lead to remission. This is achieved by reducing fat in the liver and pancreas, which allows beta-cells to function better. While not guaranteed for everyone (especially those on insulin), it is a viable goal to discuss with your healthcare provider.

Three months of supervised moderate-intensity physical exercise attenuates adipose tissue inflammation (decreased IL-6 and TNF-α) in obese adults, regardless of diabetes status, though it differentially modulates Heat Shock Protein 60 (HSP60) expression based on diabetic status.

Engage in 40 minutes of moderate exercise (keeping heart rate at 65-80% of max) three times a week. This specific protocol has been shown to reduce inflammation in fat tissue for obese individuals, whether they have diabetes or not. Supervision is recommended to ensure safety and correct intensity.

Gut peptides (specifically GLP-1 and GIP) modulate hedonic feeding and reward-seeking behavior, extending beyond homeostatic satiety, which provides a mechanism for the significant weight loss observed with GLP-1/GIP receptor agonists.

Your brain's reward system for food is biologically regulated by hormones from your gut. Medications like GLP-1 agonists work not just by making you feel full, but by dampening the brain's reward response to food cues, making it easier to resist high-calorie foods without relying solely on willpower.

Leucine acts as the primary trigger for muscle protein synthesis by activating the mTORC1 pathway, and increasing leucine content in lower-quality proteins can restore the anabolic response in older adults.

Ensure your meals contain enough leucine, the 'trigger' for muscle building. High-quality proteins like whey, eggs, and meat are naturally rich in leucine. If you rely on plant proteins or lower-quality sources, you may need to consume larger portions or combine them to get enough leucine, especially as you age.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) reduce systemic and tissue inflammation through mechanisms that are partially independent of weight loss and metabolic improvements.

GLP-1 medications like semaglutide and liraglutide offer health benefits beyond just weight loss. They directly reduce inflammation in your body, which helps protect your heart, kidneys, and joints. This happens through direct actions on your immune system and nerves, not just by making you thinner. Even if your weight stays the same, you may still receive these protective anti-inflammatory effects.

Medication reduction is a prominent and immediate benefit of VLCKD, often occurring before significant weight loss or A1c improvement is sustained, and may blunt the observed A1c response in long-term studies.

If you have Type 2 Diabetes, starting a very low-carb diet (<50g carbs/day) often leads to a rapid need to reduce or stop diabetes medications, sometimes before you lose much weight. This is a good thing, but it requires close monitoring by your doctor to avoid hypoglycemia. Do not stop your medications on your own; work with your provider to adjust doses as your blood sugar improves.

GLP1/Estrogen (GLP1/E) multi-agonist therapy provides superior metabolic improvement in PCOS models compared to GLP1 monotherapy, dual/triple agonists, and metformin, achieving significant weight loss, fat mass reduction, and improved insulin sensitivity without gastrointestinal distress.

For individuals with PCOS and metabolic issues, GLP1/Estrogen multi-agonist therapy appears to be a highly effective treatment option, significantly outperforming standard care like metformin in reducing weight, fat, and improving insulin sensitivity. While currently studied in mice, this suggests a promising future therapeutic avenue for managing PCOS-related metabolic complications.

GLP-1 receptor agonists (GLP-1RAs) including semaglutide 2.4 mg and tirzepatide induce significant weight loss (12-20%) and improve metabolic comorbidities, but discontinuation of therapy leads to rapid weight regain, indicating that obesity treatment with these agents requires long-term or lifelong administration.

GLP-1 medications like semaglutide (2.4 mg weekly) and tirzepatide are highly effective for weight loss, achieving 12-20% body weight reduction in clinical trials. However, these drugs treat obesity as a chronic condition; stopping treatment typically leads to rapid weight regain. Therefore, successful long-term management likely requires continuous, lifelong therapy. Side effects like nausea are common but manageable through slow dose escalation. Oral versions are emerging to address injection aversion.

Visceral Adipose Tissue (VAT) is a stronger predictor of metabolic syndrome and cardiovascular disease risk than total fat mass or BMI, particularly in Asian populations where VAT accumulation occurs at lower BMI thresholds.

Focus on reducing visceral fat, not just total weight. If you are Asian or older, your BMI might be 'normal' while your visceral fat is high. Use waist circumference or body composition scans to monitor VAT. Reducing VAT through exercise and diet is critical for lowering metabolic syndrome risk.

Psychogenic factors, particularly stress and PTSD, are decisive in the development of obesity through mechanisms involving high cortisol and sympathetic overactivity.

If you struggle with stress or PTSD, recognize that these mental health challenges can biologically drive weight gain through cortisol. Addressing mental health through therapy or stress management is a critical part of obesity treatment.

High baseline insulin secretion predicts greater long-term weight gain, particularly when consuming high-glycemic-index diets, supporting the carbohydrate-insulin model of obesity pathogenesis.

If you have high insulin levels, focus on reducing the glycemic load of your diet. High-glycemic foods may trigger excessive insulin secretion, promoting fat storage and weight gain, especially in those predisposed to insulin resistance.

In overweight and obese women, twice-daily exenatide treatment yields long-term weight loss outcomes similar to a hypocaloric diet with matched placebo injections, with no significant difference in the proportion of super responders (≥10% weight loss).

For overweight women, twice-daily exenatide does not guarantee better long-term weight loss than a strict hypocaloric diet alone. In fact, the study showed similar rates of significant weight loss (≥10%) between the drug and diet groups. The high response in the diet group suggests that the ritual of pre-meal injections may aid adherence. Patients should weigh the burden of daily injections against the potential benefit, as diet alone can be highly effective for early responders.

In Type 2 Diabetes, the adoption of newer glucose-lowering medications (GLP-1 agonists and SGLT2 inhibitors) is associated with a significant decline in fracture incidence rates, particularly in men and women under 50 and over 70.

If you have Type 2 Diabetes, discuss with your doctor whether your current medication increases your fracture risk. The data suggests that switching to newer classes of drugs, specifically GLP-1 agonists or SGLT2 inhibitors, is associated with a significant reduction in fracture rates compared to older medications like sulfonylureas.

GLP-1 receptor agonists (specifically liraglutide and semaglutide) improve histological features of NASH and achieve resolution of NASH without worsening fibrosis in adults with or without type 2 diabetes.

If you have NASH, GLP-1 agonists like semaglutide or liraglutide are proven to improve liver health, potentially resolving the disease without worsening scarring. They are taken as injections (daily or weekly). While they can cause nausea, the liver benefits are substantial, especially if you have type 2 diabetes or obesity. Consult your doctor for dosing.